Registry assessing therapies for atopic dermatitis in Spain

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry collects data on the safety and effectiveness of systemic therapies for atopic dermatitis, including both short and long-term outcomes. It aims to evaluate the impact of these treatments on the quality of life for both children and adults. The study also investigates the safety of topical therapies and the effectiveness of various care methods, including patient training. By gathering this information, the registry seeks to inform treatment guidelines and support shared decision-making between patients and healthcare providers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Paediatric and adult patients with atopic eczema who due to the severity of their disease and/or impact on quality of life are commencing on or switching to a specific systemic immuno-modulatory agent (e.g. CyA, AZA, MTX or new/biologic treatments) for the first time in their life (might have received others, but not this specific one).
2. Diagnosis of atopic eczema in keeping with the UK/Irish diagnostic criteria.
3. Willingness to comply with all study requirements.

Exclusion Criteria:

1. Insufficient understanding of the study by the patient and/or parent/guardian.
2. Patients who are currently participating in a randomised clinical trial.
3. Intention to move to a different geographical area in a short-term (next 3 months).

Where it's running

• Hospital Universitari Germans Trias i Pujol
  Badalona, Barcelona, Spain Recruiting
• Hospital General Universitario de Alicante
  Alicante, Spain Recruiting
• Hospital del Mar IMIM
  Barcelona, Spain Recruiting
• Hospital Universitario de Gran Canaria Dr Negrín
  Las Palmas, Spain Recruiting
• Hospital Infanta Leonor
  Madrid, Spain Recruiting
• Hospital Universitario de la Princesa
  Madrid, Spain Recruiting

Study contacts

• Study coordinator: Ignacio Garcia-Doval
• Email: investigacion@aedv.es
• Phone: 34915 44 62 84

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AR100DP1 cream for mild to moderate atopic dermatitis

  This study tests whether a 0.5% AR100DP1 topical treatment can help people with mild to moderate atopic dermatitis better than placebo over 14 days.

  Recruiting Phase 2 Arjil Pharmaceuticals LLC · Taipei, Taiwan and 1 other locations · NCT07914088

• 611 in Chinese children with moderate to severe atopic dermatitis

  A Phase 3 study tests whether 611 helps kids aged 2 to under 12 with moderate to severe atopic dermatitis compared with a placebo.

  Recruiting Phase 3 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Beijing, Beijing Municipality and 4 other locations · NCT07767253

• First-in-human test of DCY636 in healthy adults and in people with moderate to severe atopic dermatitis

  This study will test whether DCY636 is safe and tolerated in healthy adults and whether it can be safely given to people with moderate to severe atopic dermatitis.

  Recruiting Phase 1 Novartis · Fukuoka · NCT07604324

• Camoteskimab in adults with moderate-to-severe atopic dermatitis

  This trial tests different doses of camoteskimab versus placebo to see if it helps adults with moderate-to-severe atopic dermatitis who have not fully responded to standard treatments.

  Recruiting at 31 sites Phase 2 Apollo Therapeutics Ltd · Birmingham, Alabama and 84 other locations · NCT07599813

• Testing 611 for moderate to severe atopic dermatitis in Chinese adolescents

  This test will see if 611 helps Chinese adolescents (ages 12–17) with moderate to severe atopic dermatitis compared with a matching placebo over about 64 weeks.

  Recruiting at 3 sites Phase 3 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Beijing, Beijing Municipality and 2 other locations · NCT07042126

• Abrocitinib for moderate-to-severe atopic dermatitis after inadequate response to biologics

  This study will try abrocitinib in adolescents and adults (≥12 years) with moderate-to-severe atopic dermatitis who didn't respond to or couldn't tolerate up to two biologic treatments to see how it works in routine care.

  Recruiting Pfizer · San Diego, California · NCT06899204

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.